Barclays lowered the firm’s price target on DaVita (DVA) to $160 from $169 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says DaVita’s treatment growth and revenue per treatment were revised down as cyberattack disruptions drove higher missed treatment rates and revenue cycle challenges.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA: